News|Articles|February 10, 2023
SCOPE 2023: Challenging Operational Aspects of Clinical Trials
Author(s)Lisa Henderson
Len Rosenberg, head of clinical operations at Beat AML, reveals how changing the backbone treatment to a different regimen is beneficial to the patient, in terms of the safety with the same efficacy.
Advertisement
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, explains the operational obstacles that come with clinical trials, including background treatment dosages.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Subcutaneous Saphnelo Shows Positive Phase III Results in Systemic Lupus Erythematosus
2
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
3
ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials
4
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
